



## **Integra LifeSciences Schedules Conference Call for Tuesday, August 6 to Discuss Second Quarter 2002 Financial Results and Update Forward-Looking Financial Guidance; Announces Participation in Adams, Harkness & Hill Annual Summer Seminar**

PLAINSBORO, N.J.-July 29, 2002-- Integra LifeSciences Holdings Corporation (NASDAQ: IART - news) announced that it has scheduled a conference call for 9:00 AM EST on Tuesday, August 6 to discuss financial results for the second quarter ended June 30, 2002 and to update forward-looking financial guidance. Financial results for the second quarter 2002 will be announced via a news release issued before the market opens on August 6.

The upcoming conference call, which will be hosted by Stuart Essig, President and Chief Executive Officer of Integra, is open to all listeners and will be followed by a question and answer session. Additional forward-looking information may be discussed in the question and answer session following the call.

Access to the live call is available by dialing (973) 582-2729 or through a listen-only webcast via a link provided on the home page of Integra's website at [www.Integra-LS.com](http://www.Integra-LS.com). A replay of the conference call will be accessible starting one hour following the live event. Access to the replay is available through August 20, 2002 by dialing 973-341-3080 or through the webcast accessible on our home page.

Integra also announced today that it is scheduled to present at the Adams, Harkness & Hill Annual Summer Seminar at the Marriott Long Wharf Hotel in Boston, MA, on Tuesday, August 6 at 11:00 AM ET. The presentation will be delivered by Stuart Essig, President and Chief Executive Officer of Integra. Access to the live presentation is available to the general public through a webcast that can be accessed through the Calendar Events link in the Investor Relations section of Integra's website at [www.Integra-LS.com](http://www.Integra-LS.com). Additionally, a replay of this webcast presentation will be available through August 20, 2002.

Mr. Essig's presentation will provide an overview of the Company's operating divisions, a review of recent financial history, including financial results from the second quarter ended June 30, 2002, and the Company's overall business strategy.

Integra LifeSciences Holdings Corporation develops, manufactures and markets medical devices, implants and biomaterials primarily used in the treatment of cranial and spinal disorders, soft tissue repair and orthopedics. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. The Company has its corporate headquarters in Plainsboro, New Jersey, with manufacturing and research facilities located throughout the world. The Company has approximately 620 permanent employees.

Statements made in the upcoming conference call may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted results. Forward-looking factors that may be discussed include, but are not limited to, expected future financial results, new product development, governmental approvals, market potential, expected sales and potential therapeutic applications of new products, and additional business acquisitions. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2001 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

Source: Integra LifeSciences Holdings Corporation

Contact:  
Integra LifeSciences Holdings Corporation  
John Bostjancic  
Senior Director of Finance